Pancreatic Cancer

  • Most pancreatic cancers form in exocrine cells. These tumors do not secrete hormones and do not cause signs or symptoms. This makes it hard to diagnose this type of pancreatic cancer early.
  • According to the statistics of CDC of United States, the incidence rate of pancreatic cancer is about 1.2% (Data resource: CDC)
  • The death rate of pancreatic cancer is very high and the prognosis is very poor with < 8.5% alive at 5 years, despite active surgical treatment. (Data resource: NIH)
  • It is the 3th leading cause of cancer death in United States. An estimated 43,090 death occurred in 2017。 (Data resource: ACS)

(American cancer society)

The global clinical phase 3 trial for pancreatic cancer study is “EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment”. It is granted to conduct in USA, France, Taiwan, Israel, Hungary, Russia, and Korea. It is also granted Orphan Drug Designation by US FDA and European Medicines Agency.

View clinical trial at ClinicalTrials.gov.